Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4857187
Max Phase: Preclinical
Molecular Formula: C44H47ClFN9O7
Molecular Weight: 868.37
Molecule Type: Unknown
Associated Items:
ID: ALA4857187
Max Phase: Preclinical
Molecular Formula: C44H47ClFN9O7
Molecular Weight: 868.37
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCN(C(=O)CCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)CC1
Standard InChI: InChI=1S/C44H47ClFN9O7/c1-2-37(56)51-34-24-29-33(48-26-49-41(29)50-27-12-13-31(46)30(45)23-27)25-36(34)62-22-8-17-53-18-20-54(21-19-53)39(58)11-5-3-4-6-16-47-32-10-7-9-28-40(32)44(61)55(43(28)60)35-14-15-38(57)52-42(35)59/h2,7,9-10,12-13,23-26,35,47H,1,3-6,8,11,14-22H2,(H,51,56)(H,48,49,50)(H,52,57,59)
Standard InChI Key: YTNYTUGBAXJPBN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 868.37 | Molecular Weight (Monoisotopic): 867.3271 | AlogP: 5.67 | #Rotatable Bonds: 18 |
Polar Surface Area: 195.27 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 4 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.55 | CX Basic pKa: 6.88 | CX LogP: 4.89 | CX LogD: 4.78 |
Aromatic Rings: 4 | Heavy Atoms: 62 | QED Weighted: 0.05 | Np Likeness Score: -1.18 |
1. Qu X, Liu H, Song X, Sun N, Zhong H, Qiu X, Yang X, Jiang B.. (2021) Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems., 218 [PMID:33773286] [10.1016/j.ejmech.2021.113328] |
2. Zhao HY, Wang HP, Mao YZ, Zhang H, Xin M, Xi XX, Lei H, Mao S, Li DH, Zhang SQ.. (2022) Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands., 65 (6.0): [PMID:35254067] [10.1021/acs.jmedchem.1c01827] |
Source(1):